Status:
TERMINATED
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms....
Detailed Description
Study was terminated due to difficulty in enrolling the targeted number of patients on March 1, 2005, last subject last visit date was Feb.16, 2005. There were no safety concerns involved in the decis...
Eligibility Criteria
Inclusion
- confirmed diagnosis of schizophrenia according to DSM-IV-IV from patient's medical files
- subjects with current treatment with typical or atypical neuroleptics which should be changed
Exclusion
- patients with significant cardiovascular illness (recent acute myocardial infarction, uncompensated heart failure, cardiac arrhythmia)
- in the patients' history clinically significant ECG abnormalities particularly prolongation of QT interval of more than 500 ms
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00159757
Start Date
November 1 2003
End Date
February 1 2005
Last Update
February 21 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Budapest, Hungary
2
Pfizer Investigational Site
Debrecen, Hungary
3
Pfizer Investigational Site
Esztergom, Hungary
4
Pfizer Investigational Site
Kecskemét, Hungary